SciELO - Scientific Electronic Library Online

 
 número62Selección de un ciclotrón para la producción de radionúclidos de uso en medicina nuclear. Experiencia CubanaAnálisis de seguridad radiológica de una instalación PET/CT mediante el empleo de la matriz de riesgo índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Nucleus

versión impresa ISSN 0864-084Xversión On-line ISSN 2075-5635

Resumen

CRUZ ARENCIBIA, Jorge; CRUZ MORALES, Amed; IZQUIERDO PEREZ, Jorge  y  MORIN ZORRILLA, José. Quality criteria of the radiopharmaceutical suspensions used in radiosynoviorthesis. Nucleus [online]. 2017, n.62, pp.34-37. ISSN 0864-084X.

The quality criteria of radioactive dispersions used in radiosynovectomy are examined, taking into account the requirements of the Pharmacopoeia for the Chromic Phosphate P-32 of Mallinckrodt, recommendations for the use of approved radiopharmaceuticals of the European Association of Nuclear Medicine and data provided by others marketing firms. The behavior of two formulations of chromic phosphate, one http://img/revistas/nuc/n62/e01076217.jpg-labeled and the second http://img/revistas/nuc/n62/e02076217.jpg-labeled, from the point of view of the consistency (reproducibility) of both the radiochemical purity and the particle size distribution was assayed. It is proven that the presence of 5% of free phosphate admitted in the Mallinckrodt formulation, and extended to the presence of ionic forms of other radiopharmaceuticals of different matrices, is probably due to the inevitable effect of steam sterilization on the suspension. Based on these results and the accumulated clinical experience, it is considered that to establish the quality requirements of the radioactive suspensions for radiosynovectomy, more attention should be paid to the particle size distribution than to the percentage of free ionic forms. The first one is more related to the efficacy and safety of this kind of radiopharmaceuticals

Palabras clave : radiopharmaceuticals; bone joints; chromium phosphates; phosphorus 32; yttrium 90; quality assurance.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons